Zobrazeno 1 - 10
of 167
pro vyhledávání: '"MARTIN KORBLING"'
Autor:
Issa F. Khouri, Ken H. Young, Homer A. Macapinlac, L. Jeffrey Medeiros, Elias J. Jabbour, Roland L. Bassett, Luis E. Fayad, Betul Oran, Stefan O. Ciurea, Paolo Anderlini, Gheath Alatrash, Sairah Ahmed, Mingzhi Zhang, Martin Korbling, Alison M. Gulbis, William D. Erwin, Dawen Sui, Jad Chahoud
Progression-free survival curves for groups A, B, C, and D.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b25cff2a278558dec382ba76692db1f8
https://doi.org/10.1158/1078-0432.22469714
https://doi.org/10.1158/1078-0432.22469714
Autor:
Issa F. Khouri, Ken H. Young, Homer A. Macapinlac, L. Jeffrey Medeiros, Elias J. Jabbour, Roland L. Bassett, Luis E. Fayad, Betul Oran, Stefan O. Ciurea, Paolo Anderlini, Gheath Alatrash, Sairah Ahmed, Mingzhi Zhang, Martin Korbling, Alison M. Gulbis, William D. Erwin, Dawen Sui, Jad Chahoud
Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan (90YIT) in patients with relapsed diffuse large B-c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ac76d323f32b8c3a1080e1daa7a307d
https://doi.org/10.1158/1078-0432.c.6527318
https://doi.org/10.1158/1078-0432.c.6527318
Autor:
Issa F. Khouri, Ken H. Young, Homer A. Macapinlac, L. Jeffrey Medeiros, Elias J. Jabbour, Roland L. Bassett, Luis E. Fayad, Betul Oran, Stefan O. Ciurea, Paolo Anderlini, Gheath Alatrash, Sairah Ahmed, Mingzhi Zhang, Martin Korbling, Alison M. Gulbis, William D. Erwin, Dawen Sui, Jad Chahoud
Patient demographic characteristics and baseline disease characteristics for groups A, B, C, and D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a8b2997853e2ad21e246c9c18979a49
https://doi.org/10.1158/1078-0432.22469711
https://doi.org/10.1158/1078-0432.22469711
Autor:
Dawen Sui, Homer A. Macapinlac, Issa F. Khouri, Mingzhi Zhang, William D. Erwin, Jad Chahoud, Ken H. Young, Betul Oran, Gheath Alatrash, Stefan O. Ciurea, Roland L. Bassett, Elias Jabbour, Sairah Ahmed, Alison M. Gulbis, L. Jeffrey Medeiros, Martin Korbling, Luis Fayad, Paolo Anderlini
Publikováno v:
Clinical Cancer Research. 24:2304-2311
Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan (90YIT) in patients with relapsed diffuse large B-c
Autor:
Sairah Ahmed, Krina K. Patel, Stefan O. Ciurea, Maria Khouri, Carlos E. Bueso-Ramos, Francesco Turturro, Martin Korbling, Celina Ledesma, Elias Jabbour, Amin M. Alousi, David Marin, Barry I. Samuels, Uday R. Popat, Issa F. Khouri, Alison M. Gulbis, Roland L. Bassett
Publikováno v:
Biology of Blood and Marrow Transplantation. 23:1405-1410
In patients with chronic lymphocytic leukemia (CLL), persistence of disease after allogeneic stem cell transplantation (alloSCT) can result in poor outcomes. In an effort to improve these outcomes, patients with persistent CLL who were 90 to 100 days
Autor:
Elisabet E. Manasanch, Sheeba K. Thomas, Jatin J. Shah, Medhavi Honhar, Fabian Bock, Muzaffar H. Qazilbash, Veerabhadran Baladandayuthapani, Chitra Hosing, Sameh Gaballa, Samer A. Srour, Richard E. Champlin, Ruby Delgado, Krina K. Patel, Heather Lin, Gary Lu, Maximilian Stich, Uday R. Popat, Qaiser Bashir, Nina Shah, Robert Z. Orlowski, Martin Korbling, Berend Isermann, Gabriela Rondon
Publikováno v:
Biology of Blood and Marrow Transplantation. 22:2159-2164
The gain/amplification of the CKS1B gene on chromosome 1q21 region is associated with a poor outcome in patients with multiple myeloma (MM). However, there are limited data on the outcome of patients with CKS1B amplification after a single high-dose
Autor:
Jad, Chahoud, Dawen, Sui, William D, Erwin, Alison M, Gulbis, Martin, Korbling, Mingzhi, Zhang, Sairah, Ahmed, Gheath, Alatrash, Paolo, Anderlini, Stefan O, Ciurea, Betul, Oran, Luis E, Fayad, Roland L, Bassett, Elias J, Jabbour, L Jeffrey, Medeiros, Homer A, Macapinlac, Ken H, Young, Issa F, Khouri
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(10)
PURPOSE: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan ((90)YIT) in patients with relapsed diffuse large B
Autor:
Francesco Turturro, Martin Korbling, Barbara Pro, Oran Betul, Luis Fayad, Rima M. Saliba, Paolo Anderlini, Gabriela Rondon, Uday R. Popat, Amin M. Alousi, Amer Beitinjaneh, Issa F. Khouri, L. Jeffrey Medeiros, Michelle A. Fanale
Publikováno v:
Biology of Blood and Marrow Transplantation. 21:855-859
We studied the roles of autologous (A) and allogeneic (allo) stem cell transplantation (SCT) in the treatment of 134 patients with T cell lymphoma (TCL) at our center. For frontline SCT, 58 patients were studied. The 4-year overall survival (OS) rate
Autor:
Stefan O. Ciurea, Martin Korbling, Michelle Alvarez, Yago Nieto, Gabriela Rondon, Rima M. Saliba, Partow Kebriaei, David Marin, Issa F. Khouri, Marcelo Fernandez-Vina, Katy Rezvani, Amin M. Alousi, Marcos de Lima, Amanda Olson, Yudith Carmazzi, Uday R. Popat, Sairah Ahmed, Paolo Anderlini, Muzaffar H. Qazilbash, Qasier Bashir, Betul Oran, Elizabeth J. Shpall, Kai Cao, Chitra Hosing, Pedro Cano, Borje S. Andersson, Richard E. Champlin
Publikováno v:
Blood. 131(11)
We investigated the impact of donor-recipient HLA-DPB1 matching on outcomes of allogeneic hematopoietic stem cell transplantation with in vivo T-cell depletion using antithymocyte globulin (ATG) for patients with hematological malignancies. All donor
Autor:
Issa F. Khouri, Roland L. Bassett, Gabriela Rondon, Stefan O. Ciurea, Amin M. Alousi, Alison M. Gulbis, Sairah Ahmed, Elias Jabbour, Martin Korbling, Francesco Turturro, Paolo Anderlini, Wei Wei, Uday R. Popat, Betul Oran
Publikováno v:
Blood. 124:2306-2312
Myelosuppression, graft-versus-host disease (GVHD), and relapse remain major causes of morbidity after stem cell transplantation for relapsed lymphoma. In this phase 1/2 study, we tested the safety and efficacy of escalating doses of bendamustine (70